Premium
Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT‐C trial
Author(s) -
Goodman Zachary D.,
Stoddard Anne M.,
Bonkovsky Herbert L.,
Fontana Robert J.,
Ghany Marc G.,
Morgan Timothy R.,
Wright Elizabeth C.,
Brunt Elizabeth M.,
Kleiner David E.,
Shiffman Mitchell L.,
Everson Gregory T.,
Lindsay Karen L.,
Dienstag Jules L.,
Morishima Chihiro
Publication year - 2009
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.23211
Subject(s) - chronic hepatitis , medicine , fibrosis , hepatitis c , gastroenterology , pathology , virology , virus
Computer‐assisted morphometry can provide precise measurement of hepatic fibrosis on a continuous scale. Previous morphometric studies of large cohorts of patients with treatment refractory chronic hepatitis C have shown a mean increase in fibrosis of 30% to 58% in 1 year. The aim of the present study was to quantify fibrosis progression in biopsy specimens obtained over 1.5 to 5 years from three groups of patients with baseline bridging fibrosis or cirrhosis (Ishak stages 3‐6) enrolled in the Hepatitis C Antiviral Long‐term Treatment Against Cirrhosis Trial. The main group of 346 lead‐in nonresponders (viremic after 24 weeks of peginterferon‐ribavirin therapy) had a mean fibrosis increase of 61% over pretreatment baseline after 2 years and 80% after 4 years. In contrast, the 78 breakthrough/relapse patients (undetectable serum hepatitis C virus RNA after 24 weeks of peginterferon‐ribavirin and receiving antiviral therapy for 48 weeks) showed a mean increase in fibrosis of 48% when biopsied 36 months from pretreatment baseline but no further increase at 60 months. Finally, the 111 express patients with baseline biopsies following unsuccessful peginterferon‐ribavirin outside the trial had significantly more baseline fibrosis than the others but an increase of only 21% after 21 months and a slight decrease at 45 months. Maintenance therapy with low‐dose peginterferon had no effect on fibrosis changes in any of the groups. Conclusion: Morphometry demonstrated complex, nonlinear changes in fibrosis over time in this heterogeneous cohort of patients with interferon‐refractory chronic hepatitis C. (H EPATOLOGY 2009.)